{"id":4315,"date":"2025-06-16T10:59:02","date_gmt":"2025-06-16T03:59:02","guid":{"rendered":"https:\/\/www.oneonco.co.id\/blog\/?p=4315"},"modified":"2025-06-19T16:35:40","modified_gmt":"2025-06-19T09:35:40","slug":"terobosan-terapi-target-kanker-paru","status":"publish","type":"post","link":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/","title":{"rendered":"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Beban pembiayaan kanker paru yang tinggi tetap menjadi prioritas global termasuk Indonesia selama beberapa tahun terakhir. Berdasarkan data Globocan 2022, kanker paru merupakan kanker terbanyak kedua setelah kanker payudara dengan hampir 40.000 kasus baru tiap tahunnya. Kanker paru terbagi menjadi dua kelompok besar berdasarkan jenis selnya, yakni Kanker Paru Karsinoma Bukan Sel Kecil (KPKBSK) dan Kanker Paru Karsinoma Sel Kecil (KPKSK). Kanker Paru Karsinoma Bukan Sel Kecil merupakan jenis kanker yang paling umum dengan angka kejadian sekitar 85%. KPKBSK dikelompokkan Kembali menjadi tiga subtype, adenokarsinoma, karsinoma sel skuamosa, dan karsinoma sel besar. Adenokarsinoma paru merupkan jumlah subtipe yang paling umum dan sekitar 40-60% pasien Asia mengalami mutasi pada gen <em>Epidermal Growth Factor Receptor<\/em> (EGFR)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EGFR atau <em>epidermal growth factor recepto<strong>r <\/strong><\/em>&nbsp;adalah protein di permukaan sel yang berfungsi dalam pertumbuhan sel. Ketika terjadi mutasi pada EGFR, sel akan mengalami pertumbuhan yang sangat cepat dan dapat menyebabkan kanker. Pada kasus kanker paru dengan mutasi EGFR, tatalaksana terapinya adalah obat yang menghambat aktivitas EGFR, yang dikenal sebagai <em>EGFR tyrosin kinase inhibitor (EGFR-TKI)<\/em>. EGFR-TKI&nbsp; digunakan sebagai terapi lini pertama pada pasien kanker paru dengan mutasi EGFR positif.&nbsp; EGFR-TKI menghambat aktivitas enzim tirosin kinase yang terlibat dalam pertumbuhan sel. Contoh obat yang masuk ke dalam EGFR-TKIs :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Generasi pertama : Erlotinib<\/strong> dan <strong>Gefitinib<\/strong><\/li>\n\n\n\n<li><strong>Generasi kedua : Afatinib<\/strong><\/li>\n\n\n\n<li><strong>Generasi ketiga : Osimertinib<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Terapi EGFR-TKIs diberikan secara oral sehingga memudahkan pasien dan memiliki efek samping yang lebih ringan dibandingkan kemoterapi. Meskipun bekerja secara spesifik, EGFR-TKIs dapat menimbulkan efek samping seperti ruam kulit, diare, mata kering, gangguan pengelihatan, serta kelelahan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Saat ini, tantangan terbesar dari penanganan kanker paru adalah resistensi terhadap EGFR-TKIs. Beberapa penyebab umum adalah munculnya mutasi baru yang memicu resistensi. &nbsp;Maka, jika terjadi progresivitas penyakit diperlukan pemeriksaan biomolekukar ulang dengan biopsi jaringan atau biopsi cairan untuk mendeteksi adanya kemungkinan mutasi baru yang muncul untuk pemilihan terapi selanjutnya.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Sumber<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ambarita, N. M., Soeroso, N. N., Ananda, F. R., Tarigan, S. P., &amp; Zalukhu, F. . Characteristics of EGFR gene mutation in lung adenocarcinoma at Adam Malik General Hospital. <em>Jurnal Respirologi Indonesia<\/em>.2022:<em>42<\/em>(3), 170-5.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00a0. <em>GLOBOCAN 2022: Cancer today<\/em>. [Internet].2022 [cited 26 April 2025]. Available from:\u00a0 https:\/\/gco.iarc.fr\/today<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beban pembiayaan kanker paru yang tinggi tetap menjadi prioritas global termasuk Indonesia selama beberapa tahun terakhir. Berdasarkan data Globocan 2022, kanker paru merupakan kanker terbanyak kedua setelah kanker payudara dengan [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":4316,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"breadcrumbs_single_post":"","page_title_panel":"","breadcrumbs_single_page":"","single_page_alignment":"","single_page_margin":"","page_structure_type":"","content_style_source":"","content_style":"","blog_post_streched_ed":"","blog_page_streched_ed":"","has_transparent_header":"","disable_transparent_header":"","vertical_spacing_source":"","content_area_spacing":"","single_post_content_background":"","single_page_content_background":"","single_post_boxed_content_spacing":"","single_page_boxed_content_spacing":"","single_post_content_boxed_radius":"","single_page_content_boxed_radius":"","disable_featured_image":"","disable_post_tags":"","disable_author_box":"","disable_posts_navigation":"","disable_comments":"","disable_related_posts":"","disable_header":"","disable_footer":"","footnotes":"","_rishi_post_view_count":2189},"categories":[36],"tags":[197,40,45,135],"class_list":["post-4315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artikel-kanker","tag-erlotinib","tag-kanker","tag-kanker-paru","tag-terapi-kanker","rishi-post"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru - Oneonco<\/title>\n<meta name=\"description\" content=\"Terapi EGFR-TKIs diberikan secara oral sehingga memudahkan pasien dan memiliki efek samping yang lebih ringan dibandingkan kemoterapi.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru - Oneonco\" \/>\n<meta property=\"og:description\" content=\"Terapi EGFR-TKIs diberikan secara oral sehingga memudahkan pasien dan memiliki efek samping yang lebih ringan dibandingkan kemoterapi.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/\" \/>\n<meta property=\"og:site_name\" content=\"Oneonco\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/OneOnco-104876148400857\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T03:59:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-19T09:35:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2025\/06\/oral-medicine.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"595\" \/>\n\t<meta property=\"og:image:height\" content=\"892\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Meliana\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Meliana\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/\"},\"author\":{\"name\":\"Meliana\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#\\\/schema\\\/person\\\/e9000df6334d981c9b506270f63981df\"},\"headline\":\"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru\",\"datePublished\":\"2025-06-16T03:59:02+00:00\",\"dateModified\":\"2025-06-19T09:35:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/\"},\"wordCount\":352,\"publisher\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/oral-medicine.webp\",\"keywords\":[\"erlotinib\",\"kanker\",\"Kanker Paru\",\"terapi kanker\"],\"articleSection\":[\"Artikel Kanker\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/\",\"url\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/\",\"name\":\"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru - Oneonco\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/oral-medicine.webp\",\"datePublished\":\"2025-06-16T03:59:02+00:00\",\"dateModified\":\"2025-06-19T09:35:40+00:00\",\"description\":\"Terapi EGFR-TKIs diberikan secara oral sehingga memudahkan pasien dan memiliki efek samping yang lebih ringan dibandingkan kemoterapi.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/oral-medicine.webp\",\"contentUrl\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/oral-medicine.webp\",\"width\":595,\"height\":892},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/terobosan-terapi-target-kanker-paru\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/\",\"name\":\"Oneonco\",\"description\":\"Oncology Total Solution\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#organization\",\"name\":\"Oneonco\",\"url\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/oneonco_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/oneonco_logo.png\",\"width\":252,\"height\":100,\"caption\":\"Oneonco\"},\"image\":{\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/OneOnco-104876148400857\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/#\\\/schema\\\/person\\\/e9000df6334d981c9b506270f63981df\",\"name\":\"Meliana\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1fc06c3d04e31475f06876042209d21c88b47fc75cdbf29dcd131091bf2cc55c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1fc06c3d04e31475f06876042209d21c88b47fc75cdbf29dcd131091bf2cc55c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1fc06c3d04e31475f06876042209d21c88b47fc75cdbf29dcd131091bf2cc55c?s=96&d=mm&r=g\",\"caption\":\"Meliana\"},\"sameAs\":[\"https:\\\/\\\/oneonco.co.id\"],\"url\":\"https:\\\/\\\/www.oneonco.co.id\\\/blog\\\/author\\\/meliana\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru - Oneonco","description":"Terapi EGFR-TKIs diberikan secara oral sehingga memudahkan pasien dan memiliki efek samping yang lebih ringan dibandingkan kemoterapi.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/","og_locale":"en_US","og_type":"article","og_title":"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru - Oneonco","og_description":"Terapi EGFR-TKIs diberikan secara oral sehingga memudahkan pasien dan memiliki efek samping yang lebih ringan dibandingkan kemoterapi.","og_url":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/","og_site_name":"Oneonco","article_publisher":"https:\/\/www.facebook.com\/OneOnco-104876148400857","article_published_time":"2025-06-16T03:59:02+00:00","article_modified_time":"2025-06-19T09:35:40+00:00","og_image":[{"width":595,"height":892,"url":"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2025\/06\/oral-medicine.webp","type":"image\/webp"}],"author":"Meliana","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Meliana","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/#article","isPartOf":{"@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/"},"author":{"name":"Meliana","@id":"https:\/\/www.oneonco.co.id\/blog\/#\/schema\/person\/e9000df6334d981c9b506270f63981df"},"headline":"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru","datePublished":"2025-06-16T03:59:02+00:00","dateModified":"2025-06-19T09:35:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/"},"wordCount":352,"publisher":{"@id":"https:\/\/www.oneonco.co.id\/blog\/#organization"},"image":{"@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2025\/06\/oral-medicine.webp","keywords":["erlotinib","kanker","Kanker Paru","terapi kanker"],"articleSection":["Artikel Kanker"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/","url":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/","name":"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru - Oneonco","isPartOf":{"@id":"https:\/\/www.oneonco.co.id\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/#primaryimage"},"image":{"@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2025\/06\/oral-medicine.webp","datePublished":"2025-06-16T03:59:02+00:00","dateModified":"2025-06-19T09:35:40+00:00","description":"Terapi EGFR-TKIs diberikan secara oral sehingga memudahkan pasien dan memiliki efek samping yang lebih ringan dibandingkan kemoterapi.","breadcrumb":{"@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/#primaryimage","url":"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2025\/06\/oral-medicine.webp","contentUrl":"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2025\/06\/oral-medicine.webp","width":595,"height":892},{"@type":"BreadcrumbList","@id":"https:\/\/www.oneonco.co.id\/blog\/terobosan-terapi-target-kanker-paru\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.oneonco.co.id\/blog\/"},{"@type":"ListItem","position":2,"name":"Mengenal EGFR-TKI: Terobosan Terapi Target pada Kanker Paru"}]},{"@type":"WebSite","@id":"https:\/\/www.oneonco.co.id\/blog\/#website","url":"https:\/\/www.oneonco.co.id\/blog\/","name":"Oneonco","description":"Oncology Total Solution","publisher":{"@id":"https:\/\/www.oneonco.co.id\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.oneonco.co.id\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.oneonco.co.id\/blog\/#organization","name":"Oneonco","url":"https:\/\/www.oneonco.co.id\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.oneonco.co.id\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2022\/10\/oneonco_logo.png","contentUrl":"https:\/\/www.oneonco.co.id\/blog\/wp-content\/uploads\/2022\/10\/oneonco_logo.png","width":252,"height":100,"caption":"Oneonco"},"image":{"@id":"https:\/\/www.oneonco.co.id\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/OneOnco-104876148400857"]},{"@type":"Person","@id":"https:\/\/www.oneonco.co.id\/blog\/#\/schema\/person\/e9000df6334d981c9b506270f63981df","name":"Meliana","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1fc06c3d04e31475f06876042209d21c88b47fc75cdbf29dcd131091bf2cc55c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1fc06c3d04e31475f06876042209d21c88b47fc75cdbf29dcd131091bf2cc55c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1fc06c3d04e31475f06876042209d21c88b47fc75cdbf29dcd131091bf2cc55c?s=96&d=mm&r=g","caption":"Meliana"},"sameAs":["https:\/\/oneonco.co.id"],"url":"https:\/\/www.oneonco.co.id\/blog\/author\/meliana\/"}]}},"_links":{"self":[{"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/posts\/4315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/comments?post=4315"}],"version-history":[{"count":2,"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/posts\/4315\/revisions"}],"predecessor-version":[{"id":4323,"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/posts\/4315\/revisions\/4323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/media\/4316"}],"wp:attachment":[{"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/media?parent=4315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/categories?post=4315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oneonco.co.id\/blog\/wp-json\/wp\/v2\/tags?post=4315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}